Exhibit
10.10


 


OPTION
AGREEMENT 


 


THIS Option Agreement is entered into this
31st day of August, 2015 by Advanced Inhalation Therapies (AIT) Ltd., a company duly incorporated under the laws
of the State of Israel (the “Company”) and Pulmonox Technologies Corporation, a company duly incorporated under
the laws of the Province of Alberta, Canada (the “Seller”); each of the Company and the Seller may be referred
to as a “Party” and jointly as the “Parties”.


 


WHEREAS          Seller
is the owner of rights and title in the Acquired IP (as defined below), and the Company is interested in evaluating the purchase
of all such rights and title from Seller who is interested in selling such rights and title;


 


WHEREAS          for
the purposes of facilitating the purchase of the Acquired IP, Seller is willing to grant the Company a certain Option (as defined
below) to purchase all of Seller’s rights and title to the Acquired IP;


 


WHEREAS          for
the purposes of further facilitating such possible purchase, during the time between the grant of the Option and its exercise or
expiration, Seller is willing to grant the Company a temporary license to use the Acquired IP during such period, as further detailed
in this Agreement;


 


WHEREAS          the
Company and the Seller wish to lay down the terms of the grant of the Option, the temporary license and of the subsequent sale
of the Acquired IP upon exercise of the Option.


 


NOW THEREFORE IT IS AGREED AS FOLLOWS:



 


		1.	Definitions



 


In this Agreement, the following terms
shall have the following meaning ascribed to them, unless the context requires otherwise:


 


		1.1.	"Acquired IP" means all of Seller's Intellectual Property as of the Effective
Date and as of the Closing (as defined below), including without limitations, the patents, patent applications and know-how identified
as such in Schedule 1.1 attached hereto.



 


		1.2.	“Affiliate” means, with respect to any party hereto, any person, organization
or entity directly or indirectly controlling, controlled by or under common control with, such party. For purposes of this definition
only, “control” of another person, organization or entity shall mean the ability, directly or indirectly, to direct
the activities of the relevant entity, and shall include, without limitation (i) ownership or direct or indirect control of fifty
percent (50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity, or (ii)
direct or indirect possession, of the power to elect or appoint fifty percent (50%) or more of the members of the governing body
of the organization or other entity.



 


		1.3.	"Approved Product" means each of the First Approved Product, the Second Approved
Product and/or the Third Approved Product that include revenues paid to the Company for nitric oxide gas for approved medical indications.
For the avoidance of any doubt, Approved Product includes nitric oxide and may include the use of a proprietary delivery device.
For example, if the First Approved Product is for chronic obstructive pulmonary disease (“COPD”), this First Approved
Product will include nitric oxide drug product and any devices necessary to deliver nitric oxide for treatment of COPD.



 


		1.4.	“Combination Product” means a product which comprises an Approved Product and
any additional products which do not qualify as Approved Products.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	 	 



     

    

 


		1.5.	"Closing" shall mean the consummation of the acquisition of the Acquired IP by
the Company from the Seller in accordance with the provisions hereof.



 


		1.6.	"Documents" means all files, documents, data, instruments, papers, books, reports,
records, tapes, microfilms, photographs, letters, budgets, forecasts, ledgers, journals, title policies, lists, regulatory filings,
operating data and plans, technical documentation (production files, design specifications, functional requirements, operating
instructions, logic manuals, flow charts, etc.), research materials, quality assurance and test procedures, user documentation
(installation guides, user manuals, training materials, release notes, working papers, etc.), marketing documentation (sales brochures,
flyers, pamphlets, web pages, etc.), complete manufacturing files in connection with the Acquired Products and other similar materials,
all to the extent related to the Acquired IP, in each case whether in tangible or electronic form



 


		1.7.	"Effective Date" means the date of this Agreement.



 


		1.8.	"Encumbrances" means any charge, lien, attachment, pledge, encumbrance, debt,
security interest, mortgage, right of way, easement, servitude, claim, right to acquire or similar restriction, including any restriction
on use, transfer, exercise of any other attribute of ownership over or in the relevant property, or any third party rights.



 


		1.9.	"Governmental Body" means any court, administrative agency or commission or other
federal, national, provincial, state, local, foreign or other governmental authority, instrumentality, agency or commission.



 


		1.10.	"Inhaled Nitric Oxide" means any and all technology related to using gaseous Nitric
Oxide for therapeutics or prevention of disease in animals and humans



 


		1.11.	"Intellectual Property" means all patents, or patent applications and any
patent issued therefrom, any divisional, continuation or continuation-in-part application, or application for a patent of addition
or another application claiming priority, directly or indirectly, from said patents and patent application, and patents issued
therefrom, and any extensions of term, patent term adjustments, supplementary patent certificates and the like of any of the foregoing;
registered and unregistered designs; registered and unregistered trade marks; copyrights; design rights; rights in and to databases;
know-how; trade secrets; purchasing information; results of development activities, whether in confidential information or otherwise;
information of a commercial nature; any materials, results, devices, production files, procedures, protocols, formulae, computer
programs, software, source code, algorithms, file structure and any other information or data regardless of form or type, including
but not limited to that of a scientific, technical nature experimental data, test data, designs, specifications, processes, manufacturing
data, production files, techniques, inventions, drawings, vendor lists, photographs, films, reports, manuals, technical writings,
sound recordings, pictorial representations, and other documentation or other representations, graphical or otherwise; and any
other information related to development, discoveries, concepts and ideas, whether or not patentable or otherwise subject to proprietary
rights or legal protection; on magnetic tape, computer memory, or in any other form, any or all subsisting or issued anywhere in
the world.



 


		1.12.	"Legal Requirements" means any applicable federal, national, state, local, municipal,
foreign, international, multinational or other constitution, law, ordinance, code, regulation, rule, order, judgment, decree, statute
or treaty.



 


		1.13.	“Net Sales means the gross consideration received from the sale or transfer of an
Approved Product by the Company or its Affiliates, on a worldwide basis, after deduction of the following expenses, provided and
to the extent such expenses are actually incurred and documented and do not exceed reasonable and customary amounts in the market
in which such sale occurred: (a) discounts and allowances to customers; (b) rebates paid to Distributors; (c) taxes; (d) freight;
and (e) refunds and returns. Net Sales includes all consideration received in respect of any sale of an applicable product,
good or service, whether such consideration is in cash, payment in kind, exchange or another form.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	2	 



     

    

 


Notwithstanding the above, for
the purposes of this definition, the transfer of an Approved Product by the Company or one of its Affiliates to another Affiliate
of the Company is not a sale; in such case, Net Sales will be determined based on the gross invoice amount of the Approved Product
first sold by the Affiliate to independent third-parties, less the deductions permitted herein.


 


In addition, the Net Sales shall
be furthermore adjusted and reduced in the event that a Approved Product is sold as part of a Combination Product as set forth
in Section 2.4 hereto.


 


		1.14.	"Permits" means any licenses, permits, consents, registrations, approvals, permissions,
certificates, applications or other authorizations.



 


		1.15.	"Proceeding" means any claim, demand, action, suit, litigation, arbitration, proceeding
(including any civil, criminal, administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry,
inquest, audit, examination or investigation.



 


		1.16.	"Product" means any Inhaled Nitric Oxide product, good or service sold by the
Company.



 


		1.17.	"Transaction Documents" means this Agreement and all agreements, documents, instruments
and certificates ancillary to or contemplated by this Agreement.



 


		2.	The Option; Transfer of Acquired IP 



 


		2.1.	Seller hereby grants the Company, effective as of the Effective Date, an exclusive option to purchase
all of the Seller's rights, title and interest in and to the Acquired IP (the "Option"). The grant of the Option
is conditioned upon Company paying Seller the sum of US$25,000 in cash within 10 days from the Effective Date (the "Option
Consideration").



 


		2.2.	The Option shall be exercisable by a written notice given by the Company to Seller to that effect
not later than within six (6) months as of the Effective Date (the "Exercise Notice" and the "Option Period",
respectively).



 


		2.3.	Subject to the exercise of the Option by the Company, in consideration for the acquisition by the
Company of the Acquired IP from the Seller:



 


		2.3.1.	The Company shall pay Seller the sum of US$500,000 in cash (the "Purchase Price")
within 3 business days from the Closing Date;



 


		2.3.2.	The Company shall issue to Seller within 3 business days from the Closing Date warrants to purchase
up to such amount of Ordinary Shares (also known as Common Shares) of the Company, in such number equal to: (A) US$1,000,000; divided
by (B) 80% of the price per share of each Ordinary Share of the Company determined for the purposes of the Company's initial public
offering (the "Exercise Price" and the "Warrant", respectively). The Warrant shall be exercisable,
in whole or in part, until the seventh anniversary as of the date of grant of the Warrant, for cash and at Exercise Price, all
in accordance with and subject to the terms and conditions of the Warrant attached as Schedule 2.3.2 hereto. In the event
that the Company shall not undergo an initial public offering within one (1) year as of the Closing Date, the Parties hereto shall
bona fide renegotiate the terms of the Warrant. Seller acknowledges that, if required by the underwriter, any shares issued to
it in connection with the exercise of the Warrant as part of the Company's initial public offering, will be subject to a standard
lock-up period not to exceed six months.  



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	3	 



     

    

 


		2.3.3.	The Company shall make the following one-time development milestone payments to Seller, upon achievement
of each relevant milestones (each, a “Development Milestone”) (the “Development Milestone Payments”):



 


		(a)	Obtainment by the Company of its first FDA approval for an Approved Product ("First Approved
Product") - $1,500,000;



 


		(b)	Obtainment by the Company of its second FDA approval for an Approved Product ("Second Approved
Product") - $1,500,000;



 


		(c)	Obtainment by the Company of its third FDA approval for an Approved Product ("Third Approved
Product") - $1,500,000;



 


		2.3.4.	The Company shall make the following one-time sales milestone payments to Seller, upon achievement
of each relevant milestones (each, a “Sales Milestone”) (the “Sales Milestone Payments”):



 


		(a)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$20,000,000 worldwide,
per all First Approved Product - US$1,500,000.



 


		(b)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$75,000,000 worldwide,
per all First Approved Product - US$3,000,000.



 


		(c)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$125,000,000 worldwide,
per all First Approved Product - US$3,000,000.



 


		(d)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$500,000,000 worldwide,
per all First Approved Product - US$20,000,000.



 


		(e)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$20,000,000 worldwide,
per all Second Approved Product - US$1,500,000.



 


		(f)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$75,000,000 worldwide,
per all Second Approved Product - US$3,000,000.



 


		(g)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$125,000,000 worldwide,
per all Second Approved Product - US$3,000,000.



 


		(h)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$500,000,000 worldwide,
per all Second Approved Product - US$20,000,000.



 


		(i)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$20,000,000 worldwide,
per all Third Approved Product - US$1,500,000.



 


		(j)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$75,000,000 worldwide,
per all Third Approved Product - US$3,000,000.



 


		(k)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$125,000,000 worldwide,
per all Third Approved Product - US$3,000,000.



 


		(l)	The achievement by the Company of cumulative aggregate Net Sales exceeding US$500,000,000 worldwide,
per all Third Approved Product - US$20,000,000.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	4	 



     

    

 


For the avoidance of any doubt,
(i) Seller shall be entitled to receive each of the Sales Milestone Payments only one-time with respect to the achievement of each
Sales Milestone achieved by the Company; (ii) with respect to each of the First, Second and Third Approved Product, Seller may
be entitled to receive up to an aggregate amount of US$27,500,000 in total on account of the Sales Milestone Payments for each
such Approved Product.


 


For clarification purposes
only, for example:


 


(A) in the event that the Company
reaches an aggregate Net Sales of US$30,000,000 with respect to the First Approved Product, Seller shall be entitled to receive
a one-time payment of US$1,500,000, thereafter if the Company reaches an additional aggregate Net Sales of US$45,000,000 with respect
to the First Approved Product, Seller shall be entitled to receive an additional one-time payment of US$3,000,000.


 


(B) in the event that the Company
reaches an aggregate Net Sales of US$80,000,000 with respect to the First Approved Product, Seller shall be entitled to receive
a one-time payment of US$1,500,000 (for achieving the US$20,000,000 milestone) and a one-time payment of US$3,000,000 (for achieving
the US$75,000,000 milestone).


 


		2.4.	Notwithstanding the foregoing, in the event that any Approved Product is sold in a form of a Combination
Product, then the parties shall, together, determine in good faith the proportion of such Combination Product to be attributed
to the Approved Product, it being agreed that absent such mutual agreement as to the proportion of such Combination Product to
be attributed to the Approved Product, the parties shall mutually appoint an independent expert to determine such proportion. Net
Sales from such Combination Product for the purposes of determining Sales Milestone Payments thereon shall be determined by multiplying
the actual Net Sales of such Combination Product by such mutually agreed or expert-determined proportion, and the Company shall
make Sales Milestone Payments to Seller accordingly. For example purposes only, in the event that the Net Sales derived by the
Company from the sale of a certain Combination Product which is comprised from the First Approved Product and additional other
products are at a certain point US$1,000,000, and the mutually agreed or expert-determined proportion is 4/5, the Net Sales attributed
to the First Approved Product on account of the sales of such Combination Product, shall be US$800,000.



 


		2.5.	Company's obligation to make the payments set forth under Sections 2.3.3 and 2.3.4 above may be
assigned by the Company, subject to a written notice to Seller, to any third party licensing or acquiring the Acquired IP from
the Company, provided that such third party shall undertake in writing to become bound by the applicable provisions hereof. Each
such agreement shall include language pursuant to which the permitted assignee or licensee commits to make reasonable commercial
efforts to commercialize the Acquired IP.



 


		2.6.	Immediately upon exercise of the Option by the Company, at its sole discretion and at any time
during the Option period, Seller shall be deemed to have sold, assigned, and transferred to the Company all of Seller's rights,
title and interest in and to the Acquired IP, free and clear of any and all Encumbrances other than 2.5 above.



 


		2.7.	Following the exercise of the Option, Seller undertakes to take all actions, provisions and undertakings
necessary to effectuate such sale, assignment and transfer and to assist the Company in any such effort including, without limitation,
any registration of the assignment in any territory as will be required, at Company’s cost and expense. In addition, at Company’s
request, Seller shall promptly deliver to the Company true and complete files or copies of files relating to the issuance, prosecution,
maintenance, enforcement and defense to all Acquired IP in its possession, and shall thereafter promptly forward to the Company
any additional information, documents or notices it receives in connection with the Acquired IP.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	5	 



     

    

 


		2.8.	Seller hereby grants the Company, during the Option Period and to the extent that the Option was
exercised by the Company in accordance with the provisions hereof, for an additional period of six (6) month as of the end of the
Option Period, an option to purchase all of Seller's tangible assets, including inventory, machinery, equipment, tools, supplies
and other tangible property related to, or used in connection with the Acquired IP (the "Tangible Assets"), including
without limitation the Tangible Assets listed under Schedule 2.8 attached hereto, for such consideration to be agreed upon
between the parties.



 


		2.9.	Value Added Tax will be added to any payment under this Agreement pursuant to applicable law, if
applicable according to any applicable law, in which event payment by the Company shall be made, by wire transfer to a bank account
designated by the Seller to the Company in writing, subject to and against appropriate tax invoice issued by Seller.



 


		2.10.	The Company shall be entitled to deduct and withhold from any payment made pursuant to this Agreement
such amounts required to be deducted and withheld with respect to the making of any such payment under any applicable law (the
"Withholding Amount"), unless the Company is provided with an exemption from such withholding Tax or certificate
of reduced withholding in respect of each such payment at least 3 Business Days prior to the applicable payment date (a "Withholding
Tax Exemption"). Upon the request of Seller, the Company shall reasonably assist Seller in obtaining an applicable Withholding
Tax Exemption at Seller's cost. Any Withholding Amount so withheld by the Company shall be remitted to the applicable Governmental
Authorities and shall be treated for all purposes of this Agreement as having been paid to the Seller.



 


		2.11.	Seller will bear any taxes which according to applicable law should be borne by a seller in connection
with the sale of the Acquired IP and the transactions contemplated hereunder. Without derogating from the foregoing, no Party will
have any liability whatsoever for any taxes of any kind or nature, to be borne by the other Party pursuant to applicable law, whether
due, arising or payable prior, at or following the Closing Date.



 


		3.	Use of IP 



 


		3.1.	For due consideration hereby acknowledged and for purpose of facilitating the contemplated purchase
of the Acquired IP, Seller hereby grants the Company with a temporary exclusive license to use the Acquired IP for preclinical
and clinical development purposes during the License Term as defined in Section 3.2 below (the "License"), subject
to the provision of Section 2.



 


		3.2.	The term of the License (the “License Term”) shall commence as of the Effective Date
and end until the earlier of the following: (a) exercise of the Option; (b) expiry of the Option Period without execution of the
Option; or (c) termination of this Agreement without execution of the Option in accordance with the provisions of Section 9 below.



 


		3.3.	At the expense of the Company the Seller undertakes to make any document, provision and undertaking
to effectuate the License and assist the Company in any such effort including, without limitation, any license registration in
any territory as will be required.



 


		4.	Representations and Warranties



 


Except as set forth in a disclosure
schedule delivered by Seller to the Company dated as of the date hereof (the “Disclosure Schedule”) (the Disclosure
Schedule will be arranged in sections corresponding to the sections contained in this Section 5 and exceptions and disclosures
set forth in any section of the Disclosure Schedule will apply to any other section of the Disclosure Schedule to the extent the
relevance to such other section or sections is reasonably apparent), Seller hereby represents and warrants to the Company as of
the date hereof and as of the Closing Date:


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	6	 



     

    

 


		4.1.	Constitution and Compliance



 


		4.1.1.	Seller is duly incorporated and validly existing under the laws of the Province of Alberta, Canada,
in good standing and with power and authority to carry on its business as currently conducted and as currently proposed to be conducted
and to own, lease, and operate its properties. Seller has at all times carried on its business and affairs related to the Acquired
IP in all material respects in accordance with its organizational documents and all applicable Legal Requirements, and has not
breached or violated, and is not in breach or violation, of its organizational documents or applicable Legal Requirements in a
manner which may materially and adversely affect Seller in connection with the Acquired IP.



 


		4.1.2.	Seller has made available to the Company or to the Company’s legal advisor true, accurate
and complete copies of its organizational documents, as amended, as of the date of this Agreement.



 


		4.2.	Authority to Transact



 


		4.2.1.	Seller has all requisite corporate power and authority to execute and deliver the Transaction Documents,
and to carry out and perform its obligations under the Transaction Documents and to consummate the transactions contemplated thereby.



 


		4.2.2.	(i) all corporate action on the part of Seller, necessary for the authorization and execution of
the Transaction Documents by Seller, and the performance of all of Seller’s obligations under the Transaction Documents,
have been taken, and no other corporate proceeding on the part of the Seller is necessary to authorize this Agreement and the transactions
contemplated hereby; and (ii) this Agreement and the Transaction Documents constitutes, valid and legally binding obligations of
Seller, enforceable against the Seller in accordance with their terms, except as such enforceability may be limited by effect of
(a) applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’
rights and (b) general equitable principles, regardless of whether such enforceability is considered in a proceeding at law or
in equity.



 


		4.3.	Execution of Agreement



 


Neither the execution and delivery
by Seller of the Transaction Documents nor the consummation by Seller of the transactions contemplated thereby, will:


 


		4.3.1.	Violate any provisions of Seller’s organizational documents or any contract, agreement, indenture,
mortgage, instrument, note, bond, lease, license, arrangement, or undertaking of any nature, written or oral, of Seller, or cause
the acceleration, termination or modification of any contract, agreement, indenture, mortgage, instrument, note, bond, lease, license,
arrangement, or undertaking of any nature, written or oral, of Seller, in each case, related to the Acquired IP.



 


		4.3.2.	Require the consent, Permit or agreement of any Governmental Body, entity or any other third party.



 


		4.3.3.	Result in any violation of, or conflict with, or constitute a default under any term of, or result
in the creation or enforcement of, any Encumbrances upon any of the properties or assets of Seller used in connection with the
Acquired IP.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	7	 



     

    

 


		4.3.4.	Cause Seller to lose any interest in or the benefit of any asset, right, license or privilege considered
as Acquired IP it presently owns or enjoys.



 


		4.3.5.	Result in any breach or violation by Seller of any provisions of any Legal Requirements applicable
to the Seller or by which any of its assets or properties is bound or subject.



 


		4.4.	Title to Assets



 


		4.4.1.	Seller owns and has good and valid title to all of the Acquired IP, free and clear of any and all
Encumbrances other than those disclosed by Seller to Company as of the effective date of the execution of this agreement.



 


		4.4.2.	No other person or entity has any legal or equitable interest whatsoever in any of the Acquired
IP, other than those disclosed by Seller to Company as of the effective date of the execution of this agreement.



 


		4.5.	Compliance with Legal Requirements; Governmental Authorizations



 


		4.5.1.	Seller has at all times acted with best efforts with respect to the Acquired IP in compliance with
each Legal Requirement that is or was applicable to it, in all applicable jurisdictions relevant for Seller and to the Acquired
IP.



 


		4.5.2.	No event has occurred or circumstance exists that may (with or without notice or lapse of time):
(i) to Seller's knowledge, constitute or result in a violation by Seller of, or a failure on the part of Seller to comply with,
any Legal Requirement with respect to any of the Acquired IP; or (ii) could reasonably be expected to give rise to any obligation
on the part of Seller to undertake, or to bear all or any portion of the cost of, any remedial action of any nature in connection
with any Legal Requirement with respect to the Acquired IP.



 


		4.5.3.	Seller has not received, at any time, any written notice or other communication from any Governmental
Body or any other person or entity regarding: (i) any actual, alleged, possible or potential violation of, or failure to comply
with, any Legal Requirement with respect to any of the Acquired IP; or (ii) any actual, alleged, possible or potential obligation
on the part of Seller to undertake, or to bear all or any portion of the cost of, any remedial action of any nature in connection
with any Legal Requirement with respect to the Acquired IP, and to Seller's knowledge, there is no factual or legal basis for such.



 


		4.5.4.	There is no action or Proceeding pending or, to the knowledge of the Seller, threatened and no
notice has been received by the Seller that has resulted in or, could reasonably be expected to result in, suspension, non-renewal,
termination or cancellation of, with respect to, any such Permit.



 


		4.6.	Litigation



 


There is no Proceeding brought,
conducted or heard by or before, or otherwise involving, any Governmental Body or any arbitrator or arbitration panel of any kind,
at law or in equity (including actions or Proceedings seeking injunctive relief), pending or, to the knowledge of Seller, threatened,
against, or involving Seller or any properties, assets or rights of Seller, to the extent consisting part of the Acquired IP, and
Seller is not subject to any continuing order of, consent decree, settlement agreement, or other similar written agreement with,
or to the knowledge of Seller, continuing investigation by, any Governmental Body, or any judgment, order, writ, injunction, decree,
or award of any Governmental Body or arbitrator to the extent related thereto nor is it a party thereto.


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	8	 



     

    

 


		4.7.	Intellectual Property 



 


		4.7.1.	Schedule 4.7.1 contains a true and complete description as of the date of this Agreement
and as of the Closing Date of:



 


		(a)	All registered copyrights, registered patents, patent applications, registered trademarks, registered
service marks, and registered trade names owned by Seller.



 


		(b)	The jurisdictions in which any applications for patents or registration of any Acquired IP has
been made, including the respective application numbers and dates.



 


		(c)	The jurisdictions in which the Acquired IP has been registered, including the respective patent
or registration numbers and dates.



 


		(d)	All parties to whom Seller has delivered any copies of the source code constituting part of the
Acquired IP during the past three (3) years, whether pursuant to an escrow arrangement or otherwise, or parties (other than
Employees) who have the right to receive such source code.



 


		(e)	All current products, constituting part of the Acquired IP made commercially available by Seller
or currently under development by Seller, are as described in Schedule 4.7.1(e) ("Acquired Products").



 


		(f)	Seller is the sole and exclusive owner of all of the Acquired IP. Seller has sole, full and clear
title to all of such items of the Acquired IP, free and clear of any Encumbrances, and upon Closing, the Company will possess
sole, full and clear title to all of such items of the Acquired IP, free and clear of any Encumbrances, without the need to obtain
any third party or Governmental Body consent or approval, except as may be required under Legal Requirements applicable to the
Company in connection with Company's activity. The Acquired IP constitutes all of the Seller Intellectual Property. The Seller
has taken all reasonable steps to protect its rights in all of the Acquired IP, including making all filings and paying
all fees required by any Governmental Body with respect to registered Acquired IP.



 


		4.7.2.	All granted and issued patents and all registered mask works and copyright registrations constituting
part of the Acquired IP are valid and subsisting. Without limiting the generality of the foregoing, and in connection with such
Intellectual Property:



 


		(a)	Seller has not engaged in patent misuse or any fraud in connection with any registered patents.



 


		4.7.3.	Seller has the right to use, sell, license, assign, transfer, convey or dispose of the Acquired
IP.



 


		4.7.4.	Seller has taken all necessary and appropriate steps to protect and preserve the confidentiality
of the Acquired IP.



 



    	IP Acquisition Option Agreement – AIT - Pulmonox
	9	 



     

    

 


		4.7.5.	Seller has secured valid written assignments or licenses, from all employees and consultants of
Seller who contributed to the creation or development of the Acquired IP. To Seller's knowledge, Seller does not make use, nor
has it made any use, of any invention or other creation of any employees or consultants thereof, made by such employee or consultant
prior to their employment or engagement by Seller and with respect to which Seller has not secured a right to use such invention
or creation from such employee or consultant.



 


		4.7.6.	As of the date of this Agreement and as of the Closing, no person has asserted or threatened to
assert any claims with respect to the Acquired IP or any part thereof: (i) contesting the right of Seller to use, exercise, sell,
license, transfer or dispose of any of the Acquired IP; (ii) challenging the ownership, validity or enforceability of any of the
Acquired IP; or (iii) alleging any claim of infringement, violation, or misappropriation of the Acquired IP. None of the Acquired
IP is subject to any outstanding order, judgment or decree restricting in any manner the licensing, assignment, transfer or conveyance
thereof by Seller in a manner which may interfere with the provisions hereof.



 


		4.7.7.	To Seller's knowledge, there has not been and as of the date of this Agreement and as of the Closing
Date, there is no unauthorized use, infringement, violation or misappropriation of any of the Acquired IP by any third party. Seller
has not brought any actions or lawsuits, or asserted any claims alleging (i) infringement, violation or misappropriation of any
of the Acquired IP; or (ii) breach of any license, sublicense or other agreement authorizing another party to use the Acquired
IP.



 


		4.7.8.	Neither the execution, delivery or performance of the Transaction Documents, nor the consummation
of the transactions contemplated thereby, will, with or without notice or lapse of time, result in or give any other person or
entity the right or option to cause or declare: (i) a loss of, or Encumbrance on, any Acquired IP; (ii) a breach of any contract
or agreement relating to the Acquired IP to which Seller is a party or by which it is bound; (iii) the release, disclosure or delivery
of any of the Acquired IP by or to any escrow agent or other person or entity; or (iv) the grant, assignment or transfer to any
third party of any license or other right or interest under, to or in any of the Acquired IP.



 


		4.7.9.	Seller has made available to the Company or the Company’s legal advisor accurate, full and
complete copies of the following Documents relating to the Acquired IP and the Acquired Products:



 


		(a)	Any patent clearance for any Acquired Product.



 


		(b)	Any non-infringement or invalidity opinions related to third party patents drafted as a result
of an Acquired Product clearance or third party patent assertion.



 


		(c)	Any letter, notification or correspondence to Seller from any third party or from Seller to any
third party regarding infringement of the Acquired IP.



 


		4.7.10.	Seller has not provided or disclosed the source code of any software used or embedded in the Acquired
IP or the Acquired Products to any person or entity other than their respective employees and authorized consultants and contractors.
No contract or agreement grants any third party any exclusive rights, whether or not limited in time or territory, with respect
to any of the Acquired Products or the Acquired IP. The Seller has no liability with respect to, or is required to pay, any royalties,
commissions, or similar payments to any person or entity in connection with any sale, distribution, license or development of the
Acquired Products or Acquired IP.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	10	 



     

    

 


		4.8.	Brokers and Finders



 


Seller has
no Liability or obligation to pay any fees, commissions or similar payments to any broker, finder or agent in connection with the
transactions contemplated hereunder.


 


		4.9.	Due Diligence Materials. 



 


Seller has
provided to the Company or its representatives, all documents held by Seller of the character and type requested by the Company
in connection with its "due diligence" investigation of the Seller and there are no documents in the possession of the
Seller or any of its respective agents or representatives of a character or type described in such requests which have not been
so provided to the Company or its representatives.


 


		4.10.	Full Disclosure



 


The representations
and warranties made by Seller in this Agreement, when read together in their entirety, do not contain as of the date of this Agreement
and as of the Closing Date any untrue statement of a material fact, or omit as of the date of this Agreement to state a material
fact necessary to make the statements contained herein not misleading, in light of the circumstances under which they were made.


 


		5.	Prosecution and Maintenance of Patent Rights



 


		5.1.	During the Option Period, Seller shall (i) at the written request of the Company, prepare, file,
prosecute and maintain patent applications and patents covered by the Acquired IP in any country, if available, at the Company’s
cost, (ii) shall take action to actively maintain (i.e., maintenance and annuity fees paid) and prosecute all of the Acquired IP,
(iii) shall not neglect nor allow abandonment on any of the Acquired IP, (iv) regularly notify the Company of the status of all
pending applications and existing applications and patents constituting part of the Acquired IP, (v) immediately share with the
Company all correspondence regarding any of the Acquired IP, all for a maximum of $20,000 USD.



 


		5.2.	During the Option Period, Seller shall not prepare, file, prosecute, abandon or maintain patent
applications and patents covered by the Acquired IP in any country, unless such action is made (i) in full cooperation with the
Company, and (ii) subject to the Company’s prior written consent, which shall not be unreasonable withheld.



 


		5.3.	Seller and any of its assignees and/or licensees shall not make any priority claims based on any
Acquired IP, without the Company’s prior written consent.



 


		6.	Restrictive Covenants of Seller



 


		6.1.	Confidentiality.



 


During the Option Period and
for seven (7) years thereafter, to the extent that the Option was exercised by the Company in accordance with the terms hereof,
Seller shall not, directly or indirectly, and shall cause its respective directors, officers, employees, agents and representatives,
directly or indirectly, and shall cause their respective directors, officers, employees, agents and representatives not to (i)
disclose; or (ii) use for its own benefit, or for the benefit of any other person or entity, any trade secret, data or information,
whether written, oral or in other form, including without limitation, technology, copyrights, know how, trade secrets, intellectual
property, whether registered or not, designs, formulae, methods, experimental works or specifications, discoveries, samples, processes,
techniques, developments, production, marketing and sale methods, business plans, prices and pricing methods, customer lists, supplier
information, or any similar information, to the extent relating to the Acquired IP (including operations, activities, technology,
plans, products or financial affairs) (the "Confidential Information"), without limitation of time; unless such
Confidential Information is or becomes part of the public domain without the fault of Seller and except as required by applicable
law. Seller acknowledges that the Company is in the process of preparing for an initial public offering of its shares to the public
and accordingly may be required by securities laws and / or the U.S. Securities and Exchange Commission (the “SEC”)
to file this Agreement, and further consents to the filing of the Agreement, if so required in the Company’s discretion.
In the event that the filing of this Agreement is so required, the Parties shall agree in good faith what parts of the Agreement
the Company should request the SEC to be kept confidential in light of the confidential information included in such parts on the
one hand and the type of information the SEC agrees to redact from agreements such as the Agreement on the other hand.


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	11	 



     

    

 


		6.2.	Non-Compete.



 


During the Option Period and
thereafter, provided that the Option was exercised by the Company in accordance with the terms hereof, for an additional period
of four (4) years as of the Closing Date, Seller or any person or entity acting on its behalf shall not (except as provided in
this Agreement, Schedule 6.2, or any other Transaction Document):


 


		6.2.1.	Engage (whether as an owner, operator, manager, employee, officer, director, consultant, advisor,
representative or otherwise), directly or indirectly anywhere in the world (including each and every county thereof as if individually
named herein) in any business in competition with the Company; provided that ownership of less than 5% of the outstanding stock
of any publicly-traded corporation shall not be deemed to be engaging solely by reason thereof in any of its business and shall
not be a violation of the provisions hereof.



 


		6.2.2.	Contact, encourage or solicit any consultant, independent contractor, agent, lessor, licensor,
supplier, investigator, distributor, reseller, or other business associate who is employed or engaged by the Company (other than
by a general solicitation directed to the public at large through the mailing or other means of distribution of a letter, pamphlet,
handbill, circular or other written or printed media), to terminate or modify his, her or its respective employment, engagement
or business relationship therewith;



 


		6.2.3.	Contact, encourage or solicit any employee, who is employed or engaged by the Company (other than
by a general solicitation directed to the public at large through the mailing or other means of distribution of a letter, pamphlet,
handbill, circular or other written or printed media) to terminate, modify or cease to provide any services to the Company, or
otherwise to be engaged by Seller or provide it any services; and



 


		6.2.4.	Contact, encourage, or solicit any customer of the Company to terminate or modify such customer’s
business relationship with the Company.



 


		6.3.	Exclusivity.



 


From the date hereof and until
the earlier of termination or expiration hereof and the Closing Date, Seller and its respective officers, directors, employees,
agents or other representatives acting on its behalf, shall not consummate any transaction involving the sale, transfer, license,
pledge or other disposition, as the case may be, of any assets comprising of the Acquired IP of the Seller (a "Restricted
Transaction"), or negotiate or encourage or solicit any offers for, respond to any unsolicited offers for, or conduct
any negotiations with any other person, in respect of any Restricted Transaction.


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	12	 



     

    

 


		7.	Indemnification



 


The Company shall indemnify and
hold Seller and its directors, officers, employees, agents, consultants and counsel ("Seller Indemnitees") harmless from
and against any and all liabilities, damages, losses, costs or expenses (including reasonable attorneys’ and professional
fees and other expenses of litigation and arbitration) resulting from a claim, suit or proceeding brought by a third party against
a Seller Indemnitee, arising from or occurring as a result of (i) any practice by the Company of the licenses granted or Acquired
IP herein, (ii) the development, manufacture, use, importation, marketing, sale and commercialization by the Company, its Subsidiaries
or any Sublicensee of any Product, except, in each case, to the extent caused by the willful misconduct, and or gross negligence,
and or violation of law of the Seller.


 


		8.	Closing



 


Within 7 business days following
the Exercise Notice date or at such other time and date as may be agreed by Seller and the Company in writing (the "Closing
Date"), the Closing shall take place and the Seller shall transfer to the Company appropriate assignment forms required
in order to give effect to the sale and assignment of the Acquire IP to the Company, in such forms reasonably satisfactory to the
Company;


 


		9.	Term and Termination



 


		9.1.	This Agreement shall commence upon the date hereof and shall remain in effect unless and until
(i) the expiration of the Option Period, to the extent the Company did not exercise the Option until such date; or (ii) terminated
in accordance with the terms of this Section 8 or as otherwise specifically set forth in this Agreement.



 


		9.2.	The Company shall have the right to terminate this Agremeent at any time prior to the exercise
of the Option, upon a written notice to the Seller.



 


		9.3.	The failure by either party to comply with any of the obligations contained in this Agreement shall
entitle the non-breaching party to give notice to have the default cured. If such default is not cured within ten (10) days after
the receipt of such notice, or diligent steps are not taken to cure or if by its nature such default could not be cured within
ten (10) days, the notifying party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement,
and in addition to any other remedies that may be available to it by law, pursuant to this Agreement or otherwise, to terminate
this Agreement.



 


		9.4.	The provisions under which this Agreement may be terminated shall be in addition to any and all
other legal remedies which either party may have for the enforcement of any and all terms hereof, and do not in any way limit any
other legal remedy such party may have, except as specifically specified hereunder. Termination, relinquishment or expiration of
this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any party prior
to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve any party from
obligations which are expressly indicated to survive termination or expiration of this Agreement. All obligations which are not
expressly indicated to survive termination or expiration of this Agreement shall terminate upon the termination or expiration of
this Agreement.



 


		9.5.	In the event that the Company fails to comply with any of its financial obligations hereunder,
and provided that Seller have sent the Company a written notice to that effect, stating the circumstances of such incompliance,
and the Company did not cure such incompliance within 90 days from the of receipt by it of such notice or the Company rejected
the veracity of the content of such notice, then, the Parties shall submit the said dispute to the New York International Arbitration
Centre in New York, USA, pursuant to its rules and regulations.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	13	 



     

    

 


		10.	Miscellaneous



 


		10.1.	Non-Transferability. 



 


Unless otherwise agreed in
writing, during the Option Period neither party shall assign, sub-license, pledge, lien or otherwise dispose of or transfer any
right under this Agreement.


 


		10.2.	Agreement Binding On Successors.



 


This Agreement shall be binding
on and shall inure to the benefit of the parties hereto, and their heirs, administrators, successors, and assigns.


 


		10.3.	Relationship of the Parties.



 


This Agreement shall not be
construed to make any party hereto the agent, partner, joint venture or legal representative of the other for any purpose whatsoever.
Neither party hereto is granted any express or implied right or authority to assume or create any obligation or responsibility
on behalf of or in the name of the other party, except as herein otherwise expressly provided.


 


		10.4.	Governing Law and Jurisdiction.



 


This Agreement shall be governed
by the Laws of the State of Delaware, without regard to its rules of private international Law, and each party irrevocably submits
to the non-exclusive jurisdiction of the State of New York.


 


		10.5.	Entire Agreement.



 


This Agreement constitutes
the entire agreement between the parties with respect to the subject matter hereof, and cancels and supersedes all prior negotiations,
understandings and agreements relating to the subject matter hereof.


 


		10.6.	Amendments in Writing.



 


This Agreement may not be amended
except pursuant to a written instrument signed by each of the parties.


 


		10.7.	Notices.



 


All notices or other communications
hereunder shall be in writing and shall be given in person, by registered mail (registered international air mail if mailed internationally),
by an overnight courier service which obtains a receipt to evidence delivery, or by facsimile or e-mail transmission (provided
that written confirmation of receipt is provided) with a copy by mail, addressed as set forth below:


 





	If to the Company:	Advanced Inhalation Therapies (AIT) Ltd.
	 	2 Derech Meir Weisgal,
	 	Rehovot 7632605, Israel
	 	Attention: Amir Avniel







 







	With a copy to (which shall not constitute notice):	Oded Har-Even
	 	Attorney at Law
	 	Sullivan & Worcester LLP
	 	ZAG/S&W 1633 Broadway, New York,
    NY 10019, USA



 








    	IP Acquisition Option Agreement – AIT - Pulmonox
	14	 



     

    

 





	If to Seller:	Pulmonox Technologies Corporation.
	 	#102, 10835 - 120 Street
	 	Edmonton, Alberta, Canada
	 	T5H 3P9
	 	Attention: Doug Hole







 





	With
    a copy to (which shall not constitute notice):	Hugh MacNaught
	 	2738 Saint Andrews Ave.
	 	North Vancouver, BC, V7N 1Z3, Canada







 





or such other address as any
Party may designate to the other in accordance with the aforesaid procedure. All communications delivered in person or by courier
service shall be deemed to have been given upon delivery, those given by facsimile or e-mail transmission shall be deemed given
on the Business Day following transmission with confirmed answer back, and all notices and other communications sent by registered
mail (or air mail if the posting is international) shall be deemed given ten (10) days after posting.


 


		10.8.	Expenses.



 


As between the Parties, each
Party shall be responsible for the fees and expenses (including legal, accountants’ and financial advisors’ fees and
expenses) incurred by it in connection with the preparation, negotiation, execution and delivery of this Agreement and any document
required to be executed by any of such agreements, and otherwise in connection with the consummation of the transaction contemplated
hereby.


 


		10.9.	Delays or Omissions; Waiver.



 


The rights of a Party may be
waived by such Party only in writing and specifically; the conduct of any one of the Parties shall not be deemed a waiver of any
of its rights pursuant to this Agreement or as a waiver or consent on its part as to any breach or failure to meet any of the terms
of this Agreement or as an amendment hereto. A waiver by a Party in respect of a breach by the other Party of its obligations shall
not be construed as a justification or excuse for a further breach of its obligations.


 


No delay or omission to exercise
any right, power, or remedy accruing to any Party upon any breach or default by the other under this Agreement shall impair any
such right or remedy nor shall it be construed to be a waiver of any such breach or default, or any acquiescence therein or in
any similar breach or default thereafter occurring.


 


		10.10.	Counterparts.



 


This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the
same instrument. A signed Agreement received by a Party via facsimile or electronic mail will be deemed an original, and binding
upon the Party which signed it.


 


		10.11.	No Third-Party Beneficiaries.



 


Except as otherwise set forth
herein, nothing in this Agreement shall create or confer upon any Person, other than the Parties or their respective successors
and permitted assigns, any rights, remedies, obligations or liabilities.


 


The Parties to this Agreement have caused
this Agreement to be executed and delivered as of the date above first written.


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	15	 



     

    

 


SELLER:


 


	/s/ Doug Hole	 


PULMONOX TECHNOLOGIES CORPORATION


 


By: Doug Hole


Title: Chairman


 


COMPANY:


 


	/s/ Amir Avniel	 


ADVANCED INHALATION THERAPIES (AIT) LTD.


 


By: Amir Avniel


Title: Chief Executive Officer


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	16	 



     

    

 


Schedule 1.1 (Acquired IP)


 


Pulmonox Technologies
Corporation (3701)


 





		 	Country	 	 	 	 	 	 	 	 	 	 	 	Status	 	 	 	Action
	Our Ref. 	 	File No.	 	Application	 	Publication	 	Grant	 	Renewal	 	Priority	 	Property Type	 	Assignee 	 	Req'd
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P002	 	Topical Nitric Oxide as a Treatment of Autoimmune Diseases	 	Nitric Bio	 	 
	 	 	United States	 	11/974,247	 	 	 	 	 	 	 	Abandoned	 	Abandoned	 	Viasys	 	 
	 	 	3701—2US	 	12—Oct—07	 	 	 	 	 	 	 	Failure to	 	30—Jun—13	 	Pulmonox	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Respond to	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Office Action	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P003	 	System and Elements for Managing Therapeutic Gas Administration to a Spontaneously Breathing Non Ventilated Patient	 	 
	 	 	United States	 	09/688,229	 	 	 	6,668,828	 	30—Jun—15	 	 	 	Granted	 	Pulmonox	 	30—Jun—15
	 	 	3701—3US	 	16—Oct—00	 	 	 	30—Dec—03	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P004	 	System and Method for Delivering Therapeutic Gas to a Patient	 	 	 	 
	 	 	United States	 	10/140,304	 	 	 	6,955,171	 	18—Apr—17	 	 	 	Granted	 	Pulmonox	 	 
	 	 	3701—4US	 	16—Oct—00	 	 	 	18—Oct—05	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P005	 	System for use in Administrating Therapeutic Gas to a Patient	 	 	 	 
	 	 	United States	 	10/351,755	 	 	 	7,255,105	 	14—Feb—15	 	Late Fee due	 	Granted	 	Pulmonox	 	14—Aug—15
	 	 	3701—5US	 	27—Jan—03	 	 	 	14—Aug—07	 	 	 	14—Aug—15	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P006	 	Device and Method for Treatment of Wounds with Nitric Oxide	 	 	 	 
	 	 	United States	 	11/021,109	 	 	 	7,122,018	 	17—Apr—14	 	Abandoned:	 	Abandoned	 	Sensormedics	 	 
	 	 	3701—6US	 	26—Dec—00	 	 	 	17—Oct—06	 	 	 	Failure to pay	 	17—Oct—14	 	Pulmonox	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Maintenance fee	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P007	 	Method and Apparatus for Delivery of Inhaled Nitric Oxide to Spontaneous—Breathing and Mechanically—Ventilated Patients with Intermittent Dosing	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	United States	 	11/234,849	 	 	 	7,516,742	 	14—Oct—16	 	 	 	Granted	 	Cardinal Health	 	 
	 	 	3701—7US	 	24—Nov—99	 	 	 	14—Apr—09	 	 	 	 	 	 	 	Pulmonox	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P008	 	Device and Method for Treatment of Wounds with Nitric Oxide	 	 	 	 
	 	 	United States	 	11/487,600	 	7,520,866	 	21—Oct—16	 	 	 	 	 	Granted	 	Sensormedics	 	 
	 	 	3701—8US	 	26—Dec—00	 	39924	 	 	 	 	 	 	 	 	 	Pulmonox	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P009	 	Nitric Oxide Decontamination of the Upper Respiratory Tract	 	 	 	 
	 	 	United States	 	12/004,514	 	 	 	8,043,252	 	25—Apr—19	 	 	 	Granted	 	Pulmonox	 	 
	 	 	3701—9US	 	20—Dec—07	 	 	 	25—Oct—11	 	 	 	 	 	 	 	Sensormedics	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P010	 	Intermittent Dosing of Nitric Oxide Gas	 	 	 	 
	 	 	United States	 	11/598,221	 	 	 	7,955,294	 	07—Dec—18	 	 	 	Granted	 	Sensormedics	 	 
	 	 	3701—10US	 	10—Nov—06	 	 	 	07—Jun—11	 	 	 	 	 	 	 	Pulmonox	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P011	 	Nitric Oxide Gas (gNO) as a Cosmetic and Wound Healing Agent	 	 	 	 
	 	 	United States	 	11/497,557	 	 	 	 	 	 	 	Abandoned	 	Abandoned	 	Pulmonox	 	 
	 	 	3701—11US	 	08—Jul—03	 	 	 	 	 	 	 	Failure to	 	17—Mar—11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Respond to	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Office Action	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P012	 	Use of High Dose Concentration of Gaseous Nitric Oxide	 	 	 	 
	 	 	United States	 	11/704,602	 	 	 	 	 	 	 	Abandoned	 	Abandoned	 	Pulmonox	 	 
	 	 	3701—12US	 	09—Feb—07	 	 	 	 	 	 	 	Failure to	 	01—Jan—11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Respond to	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Office Action	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P013	 	System and Elements for Managing Therapeutic Gas Administration
    to a Spontaneously Breathing Non—Ventilated Patient	 	Pulmonox	 	 
	 	 	United States	 	10/691,649	 	 	 	6,986,351	 	17—Jul—17	 	 	 	Granted	 	 	 	 
	 	 	3701—13US	 	16—Oct—00	 	 	 	17—Jan—06	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P014	 	Methods and Devices for the Delivery of Therapeutic Gases Including Nitric Oxide	 	 	 	 
	 	 	United States	 	11/713,344	 	 	 	8,079,998	 	20—Jun—15	 	Late Fee due	 	Abandoned	 	Pulmonox	 	20—Dec—15
	 	 	3701—14US	 	02—Mar—07	 	 	 	20—Dec—11	 	 	 	20—Dec—15	 	* until late fee	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	payment	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	** Late Fee	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Payment to be	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	made	 	 	 	 


 






    	
 	17	 



     

    

 


Schedule 1.1 (Acquired IP)


 


	 	 	United States 2

3701—14USD	 	13/289,956

02—Mar—07	 	          	 	 	 	 	 	Abandoned Failure to Respond to Office Action	 	Abandoned

27—Jun—14	 	Pulmonox	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P015	 	Device for Administration of Nitric Oxide to Horses Spontaneously Breathing
	 	 	United States	 	10/315,539	 	 	 	6,920,876	 	26—Jan—17	 	 	 	Granted	 	Pulmonox	 	 	 
	 	 	3701—15US	 	10—Dec—02	 	 	 	26—Jul—05	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P016	 	Nitric Oxide Decontamination of the Upper Respiratory Tract
	 	 	United States	 	11/107,618	 	 	 	7,335,181	 	26—Aug—15	 	 	 	Granted	 	Pulmonox	 	26—Aug—15	 
	 	 	3701—16US	 	26—Dec—00	 	 	 	26—Feb—08	 	 	 	 	 	 	 	Sensormedics	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P017	 	Use of Exogenous Gaseous Nitric Oxide in the Treatment and Disinfection of Biofilms
	 	 	United States	 	10/953,827	 	 	 	7,485,324	 	03—Aug—16	 	 	 	Granted	 	Pulmonox	 	 	 
	 	 	3701—17US	 	29—Sep—04	 	 	 	03—Feb—09	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P018	 	Use of Nitric Oxide Gas in an Extracorporeal Circuitry to Treat Blood Plasma
	 	 	United States	 	11/445,965	 	 	 	7,531,133	 	12—Nov—16	 	 	 	Granted	 	Pulmonox	 	 	 
	 	 	3701—18US	 	01—Jun—06	 	 	 	12—May—09	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P019	 	Use of Inhaled Gaseous Nitric Oxide as a Mucolytic Agent or Expectorant
	 	 	United States	 	11/595,108	 	 	 	8,518,457	 	27—Feb—17	 	 	 	Granted	 	Pulmonox	 	 	 
	 	 	3701—19US	 	11—May—05	 	 	 	27—Aug—13	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	United States 2

3701—19USD	 	14/010,421

11—May—05	 	 	 	 	 	 	 	Restriction Requirement due 21 Mar 2015	 	Abandoned

16—Jan—15	 	Pulmonox	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P020	 	Device and Method for Treatment of Surface Infections with Nitric Oxide
	 	 	United States	 	13/006,218	 	 	 	8,795,222	 	05—Aug—14	 	 	 	Granted	 	Sensormedics	 	 	 
	 	 	3701—20US	 	31—Oct—07	 	 	 	05—Aug—14	 	 	 	 	 	 	 	Pulmonox	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3701P021	 	Intermittent Dosing of Nitric Oxide Gas
	 	 	United States	 	13/369,205	 	 	 	Issue Notification sent July 15, 2015	 	Granted	 	Pulmonox	 	 	 
	 	 	3701—21US	 	11—May—05	 	 	 	 	 	 	 	 	 	 	 	Sensormedics	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Use of gaseous nitric oxide as an anti—cancer agent
	 	 	United States	 	11/704,791	 	 	 	 	 	 	 	 	 	Abandoned	 	Pulmonox	 	 	 
	 	 	 	 	07—Feb—09	 	 	 	 	 	 	 	 	 	25—Apr—11	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Method and Apparatus for Treatment of Respiratory Infections by Nitric Oxide Inhalation	 	 	 	Abandoned	 	Pulmonox	 	 	 
	 	 	 	 	11/591,373	 	 	 	 	 	 	 	 	 	16—Mar—09	 	 	 	 	 
	 	 	 	 	01—Nov—06	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Nitric oxide as an anti—viral agent, vaccine and vaccine adjuvant
	 	 	 	 	11/601,908	 	 	 	 	 	 	 	 	 	Abandoned	 	Pulmonox	 	 	 
	 	 	 	 	20—Nov—06	 	 	 	 	 	 	 	 	 	28—May—09	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Multi—gas delivery system
	 	 	 	 	10/148,967	 	 	 	 	 	 	 	 	 	Abandoned	 	Pulmonox	 	 	 
	 	 	 	 	07—Jun—02	 	 	 	 	 	 	 	 	 	25—Jul—05	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
	 	 	 	 	11/211,055	 	 	 	 	 	 	 	 	 	Abandoned	 	Pulmonox	 	 	 
	 	 	 	 	23—Aug—05	 	 	 	 	 	 	 	 	 	16—Mar—09	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Intermittent Dosing Of Nitric Oxide Gas
	 	 	 	 	11/596,027	 	 	 	 	 	 	 	 	 	Abandoned	 	Sensormedics	 	 	 
	 	 	 	 	10—Nov—06	 	 	 	 	 	 	 	 	 	10—Feb—11	 	Pulmonox	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	DEVICE AND METHOD FOR TREATMENT OF WOUNDS WITH NITRIC OXIDE
	 	 	 	 	11/982,430	 	 	 	 	 	 	 	 	 	Abandoned	 	Sensormedics	 	 	 
	 	 	 	 	31—Oct—07	 	 	 	 	 	 	 	 	 	31—Jan—11	 	Pulmonox	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	INTERMITTENT DOSING OF NITRIC OXIDE GAS
	 	 	 	 	13/007,273	 	 	 	 	 	 	 	 	 	Abandoned	 	Sensormedics	 	 	 
	 	 	 	 	14—Jan—11	 	 	 	 	 	 	 	 	 	03—Oct—11	 	Pulmonox	 	 	 


 






    	
 	18	 



     

    

 


Schedule 1.1 (Acquired IP)


 


Description of Proprietary Nature of Trade Secrets


 


	Device Technology	 	AeroNOx Device	 	ViaNOx-DS  Device	 	CidaNOx-II  Device	 	Pulmonox Patch

Device
	 	 	 	 	 	 	 	 	 
	Proprietary nature of the Technology Transfer	 	Experience and insight into the art of Nitric Oxide Engineering Design, Engineering build Know-How, efficient and effective standardization for safety and performance, Regulatory Approval, Product Build and Quality Control.	 	Experience and insight into the art of Nitric Oxide Engineering Design, Engineering build Know-How, efficient and effective standardization for safety and performance, Regulatory Approval, Product Build and Quality Control.	 	Experience and insight into the art of Nitric Oxide Engineering Design, Engineering build Know-How, efficient and effective standardization for safety and performance, Regulatory Approval, Product Build and Quality Control.	 	Experience and insight into the art of Nitric Oxide Engineering Design, Engineering build Know-How, efficient and effective standardization for safety and performance, Regulatory Approval, Product Build and Quality Control.
	 	 	 	 	 	 	 	 	 
	Background	 	Nitric Oxide must be delivered by an accurate and controlled means where NO and NO2 can be closely monitored. The use of Nitric Oxide as a drug required a Regulatory Approved Device specific to the desired Treatment parameters.	 	Nitric Oxide must be delivered by an accurate and controlled means where NO and NO2 can be closely monitored. The use of Nitric Oxide as a drug required a Regulatory Approved Device specific to the desired Treatment parameters.	 	Nitric Oxide must be delivered by an accurate and controlled means where NO and NO2 can be closely monitored. The use of Nitric Oxide as a drug required a Regulatory Approved Device specific to the desired Treatment parameters.	 	Nitric Oxide can be delivered by an accurate and controlled means in a highly portable manner suitable where larger devices may not be practical. The use of Nitric Oxide as a Drug requires a Regulatory Approved Device specific to the desired Treatment parameters.


 




    	
 	19	 



     

    

 


Schedule 1.1 (Acquired IP)


 


	Treatment Parameters	 	Constant flow Nitric Oxide. Highly portable Delivery System. Designed for inhaled applications of Nitric Oxide including Premature Infant use.	 	Phasic flow Nitric Oxide to match ventilator flow. Highly portable Delivery System. Designed for inhaled applications of Nitric Oxide for Adults.	 	Constant flow Nitric Oxide. Highly portable Delivery System. Designed for topical application of Nitric Oxide to the surface of the skin for Treatment of Biofilms.	 	Delivery of Nitric Oxide by means of a small portable Device for a range of application criteria.
	 	 	 	 	 	 	 	 	 
	Device Application	 	Insight into Device application and use in Nitric Oxide Medical Applications.	 	Insight into Device application and use in Nitric Oxide Medical Applications.	 	Insight into Device application and use in Nitric Oxide Medical Applications.	 	Insight into Device application and use in Nitric Oxide Medical Applications.
	 	 	 	 	 	 	 	 	 
	Design Insight	 	Insight in to considerations in Device Design.	 	Insight in to considerations in Device Design.	 	Insight in to considerations in Device Design.	 	Insight in to considerations in Device Design.
	 	 	 	 	 	 	 	 	 
	Device Prototype	 	Prototype and enabling insight into Device Construction and Production.	 	Prototype and enabling insight into Device Construction and Production.	 	Prototype and enabling insight into Device Construction and Production.	 	Prototype and enabling insight into Device Construction and Production.
	 	 	 	 	 	 	 	 	 
	Device Manufacture	 	Pulmonox have manufactured commercial Device Products in house.	 	Pulmonox have manufactured commercial Device Products in house.	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Device Documentation including Operations Manual	 	Documentation necessary for operation, training and Device Servicing	 	Documentation necessary for operation, training and Device Servicing	 	Documentation necessary for operation, training and Device Servicing	 	Documentation necessary for operation, training and Device Servicing


 




    	
 	20	 



     

    

 


Schedule 1.1 (Acquired IP)


 


	Device Approval Documentation	 	This
    Device  has Been Health Canada and FDA approved. Enabling information to provide rapid Regulatory Approval. Enabling
    information includes scientific  information
    necessary for the Regulatory Body to evaluate the Safety and Effectiveness of the Device to  obtain marketing
    clearance.	 	This Device  has Been Health Canada and FDA approved. Enabling information to provide rapid Regulatory Approval. Enabling information includes scientific information necessary for the Regulatory Body to evaluate the Safety and Effectiveness of the Device to  obtain marketing clearance.	 	Assistance with information necessary for the Regulatory Body to evaluate the Safety and Effectiveness of the Device to  obtain marketing clearance.	 	Assistance with information necessary for the Regulatory Body to evaluate the Safety and Effectiveness of the Device to  obtain marketing clearance.


 


	Nitric Oxide Drug Manufacture Technology	 	Nitric Oxide Drug Manufacture Technology	 	Nitric Oxide Drug Manufacture Process and Equipment	 	Active Product Ingredient (API)	 	Drug Master  File (DMF)
	 	 	 	 	 	 	 	 	 
	Proprietary nature of the Technology Transfer	 	Experience and insight into the art of Nitric Oxide, Engineering Design, Engineering build Know-How, efficient and effective standardization for Safety and Performance, Regulatory Approval, Process Equipment build and Quality Control.	 	Engineering Design and Operational Data for the production of High Purity Nitric Oxide.  Process Equipment Access for Duplication. Process Documentation including Operations Manual. From validated operational process.	 	Test Certification Report on Nitric Oxide produced with Engineering Design, and process manufacturing Equipment to be inspected and duplicated. Medical Grade Nitric Oxide Gas has been produced.	 	Documentation toward the development of a Drug Master File specific to Asia Regulatory Authorities and submission.


 




    	
 	21	 



     

    

 


Schedule 1.1 (Acquired IP)


 


	Background 	 	Nitric Oxide has the molecular formula NO and is the exact same molecule for all Drugs. In order for Nitric Oxide to be used as a Drug however it must be of high purity produced in a manner where it can be shown there are no unknown pollutants.	 	The manufacture of Nitric Oxide must be under a controlled and repeatable process. Operational Procedures must be outlined and followed in a specific manner.	 	Active Product Ingredient (API) is the substance in a pharmaceutical Drug that is biologically active. The method of manufacture of Nitric Oxide must deliver the desired Drug ingredient as validated through detailed testing techniques and procedures,	 	Drug Master File or DMF is a document prepared by a Pharmaceutical Manufacturer for the appropriate Regulatory Authority in the intended Drug market. The document provides the Regulatory Authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of  Human Drugs.


 


	Drug Indication

Strategies	 	Anti-Bacterial	 	Anti-Viral	 	Anti-Biofilm	 	Mucolytic
	 	 	 	 	 	 	 	 	 
	Proprietary nature of the Technology Transfer	 	Experience and insight into the art of Nitric Oxide toward Regulatory Approval as a new Drug treatment for Anti- Bacterial treatments.	 	Experience and insight into the art of Nitric Oxide toward Regulatory Approval as a new Drug treatment for Anti- Viral treatments.	 	Experience and insight into the art of Nitric Oxide toward Regulatory Approval as a new Drug treatment for Anti- Biofilm treatments.	 	Experience and insight into the art of Nitric Oxide toward Regulatory Approval as a new Drug treatment for Mucolytic treatments.


 




    	
 	22	 



     

    

 


Schedule 2.3.2: Warrant


 


Terms specified in article 2.3.2.


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	23	 



     

    

 


Schedule 2.8: Tangible Assets


 


Archived physical assets of the Seller available
on an as-is where-is basis


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	24	 



     

    

 


Schedule 4.7.1 H: Acquired Products


 


ViaNox-DS


 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	25	 



     

    

 


Schedule 6.2: Non-Compete Exceptions


 


Person: Hugh MacNaught


 


IP:


 


		1.	Use of nitric oxide to address the effects of nitric oxide deficient blood used in transfusions. The levels of nitric oxide
in stored blood begin to decline immediately upon collection. Transfusion of stored blood may result in further vasoconstriction
in the patient. Treatment with nitric oxide at the time of or immediately prior to transfusion will provide a vasodilatory effect.



 


		2.	Use of nitric oxide to improve
outcomes for free flap surgery. Free flap surgery is a method of reconstruction where tissue in one place is used to reconstruct
a defect in another place. The flap is removed with an artery and vein but at the time of being transferred it loses its blood
supply. It is then attached to an artery and vein at the reconstruction site. It is possible the artery or vein may stop working
in which case the flap tissue dies. Flap problems are most likely within the first 48 hours following the procedure and are rare
after 4 days. Treatment with nitric oxide may provide sufficient vasodilation to enable better function of the artery and vein
attached to the graft, as well as the wound site in general.



 




    	IP Acquisition Option Agreement – AIT - Pulmonox
	26